Dr. David J. Einstein, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Tufts University School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 143
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Tufts University School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
MA license 247790
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Beth Israel Deaconess Medical Center Boston, MA
- Beth Israel Deaconess Hospital - Needham Needham, MA
- Beth Israel Deaconess Hospital - Milton Milton, MA
Medical groups
- Harvard Medical Faculty Phys at Beth Israel Deaconess Med Ctr Inc (1,740 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 143
- Services billed
- 783
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 251 | 75 |
| Established patient office or other outpatient visit, 30-39 minutes | 168 | 85 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 118 | 24 |
| Telephone medical discussion with physician, 21-30 minutes | 45 | 35 |
| New patient office or other outpatient visit, 60-74 minutes | 23 | 23 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Xtandi (enzalutamide) | 55 |
| Cabometyx (cabozantinib s-malate) | 36 |
| Prednisone Other prescribers in Boston, MA | 34 |
| Abiraterone Acetate | 31 |
| Tamsulosin Hcl Other prescribers in Boston, MA | 25 |
| Orgovyx (relugolix) | 13 |
| Nubeqa (darolutamide) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $880 in total to this clinician.
| Janssen Scientific Affairs, LLC | $880 |
|---|
| Consulting Fee | $880 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Scientific Affairs, LLC May 27, 2025 | Consulting Fee ERLEADA · Oncology | $880 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $11,843 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With …
Amgen Inc. - A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC IDeate-Prostate01
Merck Sharp & Dohme LLC - PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate …
Novartis Pharmaceuticals Corporation - An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Ol…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.